PETVIVO HOLDING, INC. ANNOUNCES SPRYNG™ NOW AVAILABLE TO VETERNARIANS THROUGH MWI ANIMAL HEALTH
October 03 2022 - 7:23AM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an
emerging biomedical device company focused on the commercialization
of innovative medical devices and other therapeutics for equine
athletes and companion animals, announced today that its signature
product Spryng™ with OsteoCushion™ Technology is now available for
purchase through MWI Animal Health, a subsidiary of
AmerisourceBergen (“MWI”). MWI, a leading distributor of animal
health products and services, has Spryng available for sale
throughout the United States. Pursuant to an exclusive distribution
agreement entered into by PetVivo and MWI, MWI will inventory,
market, and promote Spryng throughout the United States.
We have shipped Spryng to veterinarians in forty
two states. "We are now excited to team-up with MWI to expand the
distribution of Spryng to veterinarians throughout the United
States. We view MWI as a strategic partner that will allow PetVivo
significant exposure to and penetration in the US animal health
market, stated John Lai, Chief Executive Officer for PetVivo. We
believe our relationship with MWI will provide veterinarians a new
tool for the management of lameness and other joint afflictions,
thereby enhancing the lives of animals and their owners alike.”
PetVivo’s innovative product, Spryng with
OsteoCushion Technology, is a veterinary medical device comprised
of millions of micronized hydrogel matrices, which are derived from
natural biocompatible components. OsteoCushion Technology provides
both reinforcing natural joint support to augment and reinforce
missing and/or damaged cartilage, as well as delivers natural
scaffolding to help address tissue defects. These attributes offer
a great solution to manage lameness and joint afflictions, such as
osteoarthritis, for equine athletes and companion animals in a
simple in-clinic administration.
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of nineteen
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG™
with OsteoCushion™ technology, a veterinarian-administered,
intraarticular injection for the management of lameness and other
joint related afflictions, including osteoarthritis, in dogs and
horses, is currently available for commercial sale.
For more information about PetVivo Holdings,
Inc. and our revolutionary product, Spryng with OsteoCushion
Technology, please contact info1@petvivo.com or visit
https://petvivo.com/
CONTACT:
John Lai, CEOPetVivo Holdings, Inc.Email:
info1@petvivo.com (952) 405-6216
Forward-Looking commercial
Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements,
including the potential listing of the Company’s common stock on
Nasdaq, are based on information currently available the Company
and its current plans or expectations and are subject to a number
of uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2022 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jul 2024 to Jul 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jul 2023 to Jul 2024